Navigation Links
IdentiGEN's DNA TraceBack(R) Receives USDA Process Verified Program Approval
Date:11/5/2007

reliable program in which meat processors, meat producers, retailers and consumers can have confidence.

The USDA Process Verified Program is based on the International Organization for Standardization's ISO 9000 series standards for documented quality management systems. There are currently 36 approved USDA Process Verified Programs. Additional information can be found at http://processverified.usda.gov/.

Though its process has been adopted by leading international grocery retailers, including Tesco and Superquinn in Ireland, IdentiGEN is a relative newcomer to the North American scene. Last May, IdentiGEN established its North American headquarters and high-technology laboratory for DNA analysis in Lawrence, Kan.

"We intend to make IdentiGEN a global company of consequence, and the USDA approval of our DNA TraceBack system marks a significant accomplishment towards this goal," said Patrick Cunningham, Ph.D., chairman of IdentiGEN Ltd.

IdentiGEN was founded in 1996 by a group of geneticists from Ireland's Trinity College, who developed a unique system that utilizes DNA analysis to support marketing of branded meat, verify country of origin and validate marketing claims and product attributes. DNA TraceBack can also be a major competitive positioning and risk-management tool for retailers, because it supports seamless and fast traceability in the event of a product recall.

About IdentiGEN

IdentiGEN Ltd., with its North American subsidiary IdentiGEN, Inc., is a privately-held venture-backed company, and a leading provider of DNA-based solutions to the agriculture and food industries. The company was founded as a spin-out from the Institute of Genetics, Trinity College, where the company's core area of expertise -- genetic identification -- was developed and is now being deployed in a variety of ways to enhance consumer confidence in the safety and quality of food products.
'/>"/>

SOURCE IdentiGEN, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/14/2008)...$12 million total funding to PBTF Institute at Duk... cure, ASHEVILLE, N.C., May 14 /PRNewswire...on (PBTF) is giving an additional $6 million grant...nging total funding for the,program to $12 million... http://www.prnewswire.com/mnr/pbtf/32347/ Duke ...
(Date:5/14/2008)...o benefit seen for prehypertensive people in morni..., May 14 (HealthDay News) -- A daily aspirin can c... bedtime, a Spanish study shows. , An aspirin t... of prehypertensive people, but the evening regime...the American Society of Hypertension annual meetin...
(Date:5/14/2008)... WILMINGTON, Del., May 14 /PRNewswire-FirstCall/...he U.S. Food and Drug Administration (FDA) has,app...r the maintenance,treatment of patients with bipol...valproex. SEROQUEL is approved by the FDA for the ...ingle agent approved by the FDA for,the treatment ...
(Date:5/14/2008)... DUBLIN, May 14 /PRNewswire-FirstCall/ -- Amarin...a private placement of American Depositary,Shares ...th several new,institutional and accredited invest...any, for up to $60 million funded over two equal t...o definitive agreements for,gross proceeds of up t...
Breaking Medicine News(10 mins):Health News:Video: Pediatric Brain Tumor Foundation Gives $6 Million Grant to Duke 2Health News:Aspirin at Bedtime Lowers Blood Pressure 2Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 2Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 3Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 4Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 5Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 6Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 7Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 8Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 9Health News:Amarin Announces Private Placement for up to $60 Million 2Health News:Amarin Announces Private Placement for up to $60 Million 3Health News:Amarin Announces Private Placement for up to $60 Million 4Health News:Amarin Announces Private Placement for up to $60 Million 5
...eaf people (RNID) has asked drug companies to find... cancer patients who survive chemotherapy. // Th...e anti-tumor agent cisplatin, which has been succe...ers in adults as well as children. Cisplatin is a ...
...er 17 issue of The Journal of Experimental Medicin...the gut. This feature may help the body prevent an...ign particle//. Fat rich foods stimulate the inte...yme called a hormone called cholecystokinin, or CC...
... that the survival rate of women with breast cance...reast cancer prior to 10 years//. The experts feel...stly due to world wide awareness for early detecti...e treatment options available due to increased res...
...at high risk of fatal and non-fatal myocardial inf...on for their decreased life expectancy//. There is...liferator-activated receptor-? (PPAR-?) could redu...zone is one such agonist used to treat type-2 diab...
Other Medicine News:Health News:Breast cancer women has shown an increase in survival rates 2
(Date:5/13/2008)...IENCE V in SPIRIT III Trial Experience Better, Lon...ombosis than Patients Tr...swire-FirstCall/ -- Long-term data,presented for t...ott,s U.S.,pivotal trial studying the XIENCE(TM) V...rated that XIENCE V continues to deliver clinicall...
(Date:5/12/2008)...lif., May 12 /- Napo,Pharma...hat it presented a,poster in collaboration with Qu...patient reported outcomes questionnaire focused on...ts of chronic diarrhea in persons living with,HIV/...oeconomics and,Outcomes Research (ISPOR) Annual Me...
(Date:5/12/2008)...wire-FirstCall/ -- GeoVax Labs, Inc. (OTC,Bulletin...development,company, announced today that it has e...reement with Fusion Capital Fund II, LLC, a Chicag...sell up to $10 million of its common stock to Fusi...d after the Securities and,Exchange Commission has...
(Date:5/12/2008).../- Arbios Systems, Inc.,(OT...ompany has received,approval from the U.S. Food an...l Device Exemption ("IDE") to begin the pivotal cl... (outside the body) liver assist,device for blood ...m,chronic liver disease., "We are pleased to have...
Breaking Medicine Technology:XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 2XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 3XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 4XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 5Napo Presents at ISPOR Meeting in Toronto 2GeoVax Secures $10 Million Financing Commitment 2GeoVax Secures $10 Million Financing Commitment 3Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 2Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 3Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 4Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 5Milady U Provides Continuing Education to Salon and Spa Professionals 12291 1Milady U Provides Continuing Education to Salon and Spa Professionals 12291 2Gene therapy trains immune system to destroy brain cancer cells and reverses behavioral deficits 12289 1Gene therapy trains immune system to destroy brain cancer cells and reverses behavioral deficits 12289 2Gene therapy trains immune system to destroy brain cancer cells and reverses behavioral deficits 12289 3Controversies in science and technology explored in new book from Mary Ann Liebert 12286 1Controversies in science and technology explored in new book from Mary Ann Liebert 12286 2Platinum Underwriters Holdings Ltd Reports Record Fourth Quarter and Year Ended December 31 2007 Financial Results 12283 1Platinum Underwriters Holdings Ltd Reports Record Fourth Quarter and Year Ended December 31 2007 Financial Results 12283 2Platinum Underwriters Holdings Ltd Reports Record Fourth Quarter and Year Ended December 31 2007 Financial Results 12283 3Platinum Underwriters Holdings Ltd Reports Record Fourth Quarter and Year Ended December 31 2007 Financial Results 12283 4Platinum Underwriters Holdings Ltd Reports Record Fourth Quarter and Year Ended December 31 2007 Financial Results 12283 5Platinum Underwriters Holdings Ltd Reports Record Fourth Quarter and Year Ended December 31 2007 Financial Results 12283 6Platinum Underwriters Holdings Ltd Reports Record Fourth Quarter and Year Ended December 31 2007 Financial Results 12283 7Platinum Underwriters Holdings Ltd Reports Record Fourth Quarter and Year Ended December 31 2007 Financial Results 12283 8Platinum Underwriters Holdings Ltd Reports Record Fourth Quarter and Year Ended December 31 2007 Financial Results 12283 9Platinum Underwriters Holdings Ltd Reports Record Fourth Quarter and Year Ended December 31 2007 Financial Results 12283 10Platinum Underwriters Holdings Ltd Reports Record Fourth Quarter and Year Ended December 31 2007 Financial Results 12283 11Platinum Underwriters Holdings Ltd Reports Record Fourth Quarter and Year Ended December 31 2007 Financial Results 12283 12
...edical,professionals seeking to treat the serious ...tive pneumonia may have a new weapon:,NKTR-061 (in...g,developed by Nektar Therapeutics (Nasdaq:NKTR).,...he use of,NKTR-061 (Inhaled Amikacin) to treat mec...ed gram-negative pneumonia were,presented today du...
...g-term,maintenance treatment of COPD bronchoconstr...l fumarate provides improved lung function,compara...lity of,life, and positive safety profile -- , NAP...,International Conference of the American Thoracic... (formoterol fumarate),Inhalation Solution, delive...
Other Medicine Technology:Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7
Microscopic scissors, curved
Back discomfort is a complaint of the past when you wear our most comfortable apron. The wide belt takes the weight off the shoulders and provides lower back support. The shoulder pads are standard f
Fluoro done? Get rid of your apron quickly and easily without breaking the sterile field. A shoulder drop-away can also be used with our Stretchy-back and cummmberbund aprons. Shoulder pads and hangi
Open armhole design with Velcro release enables removal without compromising sterile field. Loops attached at shoulders for proper hanging & storage
Medicine Products: